Back to Search
EMILY BERGSLAND, MD
MD
Medical Oncology Physician
NPI: 1295792729IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
G70524(CA)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
G70524(CA)
Education
OTHER
Class of 1989
Research & Publications (20)
Update on clinical trials targeting vascular endothelial growth factor in cancer.
PMID 15552622·Am J Health Syst Pharm·2004
6-review
Vascular endothelial growth factor as a therapeutic target in cancer.
PMID 15552621·Am J Health Syst Pharm·2004
6-review
Molecular mechanisms underlying the development of hepatocellular carcinoma.
PMID 11685745·Semin Oncol·2001
6-review
Glycemic control in patients with insulinoma treated with everolimus.
PMID 19129539·N Engl J Med·2009
8-other
Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
PMID 18987169·Endocr Relat Cancer·2009
7-preclinical
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
PMID 18815548·Pancreas·2008
4-observational
Activity of sunitinib in patients with advanced neuroendocrine tumors.
PMID 18612155·J Clin Oncol·2008
3-trial
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
PMID 18379729·Invest New Drugs·2008
3-trial
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
PMID 18279576·Clin Colorectal Cancer·2008
3-trial
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
PMID 18181045·Cancer Invest·2008
3-trial
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
PMID 17947727·J Clin Oncol·2007
3-trial
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
PMID 17686822·J Natl Cancer Inst·2007
1-meta
Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
PMID 17606198·Surg Oncol Clin N Am·2007
6-review
Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
PMID 17548034·Hematol Oncol Clin North Am·2007
6-review
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
PMID 17363191·Int J Radiat Oncol Biol Phys·2007
3-trial
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
PMID 16877721·J Clin Oncol·2006
3-trial
Targeting growth factors and angiogenesis; using small molecules in malignancy.
PMID 16770540·Cancer Metastasis Rev·2006
6-review
Pancreatoblastoma in an adult: case report and review of the literature.
PMID 16769539·J Gastrointest Surg·2006
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1600 DIVISADERO ST
SAN FRANCISCO, CA 94115 - Phone
- (415) 353-9888
Quick Facts
- NPI
- 1295792729
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile